AbbVie sets up shop in Singapore

Share this article:

AbbVie is establishing roots in Asia. The drugmaker announced Thursday that it was investing $320 million to build the manufacturing facility in Singapore—its first manufacturing site in all of Asia. The site will be focused on emerging oncology and immunology products.

The company said in a statement it expects the site will be fully operational by 2019 and will employ around 250.

AbbVie split from Abbott Laboratories in January 2013.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.